Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response

Margaux Vienne (1) , Marion Etiennot (1) , Bertrand Escalière (1) , Justine Galluso (1) , Lionel Spinelli (1) , Sophie Guia (1) , Aurore Fenis (1, 2) , Eric Vivier (3, 1, 2) , Yann M Kerdiles (1)

1 CIML - Centre d'Immunologie de Marseille - Luminy
2 Innate Pharma
3 APHM - Assistance Publique - Hôpitaux de Marseille

Natural killer (NK) cells are known to be able to kill established tumor cell lines, but important caveats remain regarding their roles in the detection and elimination of developing primary tumors. Using a genetic model of selective ILC1 and NK cell deficiency, we showed that these cells were dispensable for tumor immunosurveillance and immunoediting in the MCA-induced carcinogenesis model. However, we were able to generate primary cell lines derived from MCA-induced tumors with graded sensitivity to NK1.1 + cells (including NK cells and ILC1). This differential sensitivity was associated neither with a modulation of intratumoral NK cell frequency, nor the capacity of tumor cells to activate NK cells. Instead, ILC1 infiltration into the tumor was found to be a critical determinant of NK1.1 + cell-dependent tumor growth. Finally, bulk tumor RNAseq analysis identified a gene expression signature associated with tumor sensitivity to NK1.1 + cells. ILC1 therefore appear to play an active role in inhibiting the antitumoral immune response, prompting to evaluate the differential tumor infiltration of ILC1 and NK cells in patients to optimize the harnessing of immunity in cancer therapies.

Mots clés: innate; innate lymphoid cells (ILCs); antitumoral immunity; NK cells; ILC1

Domaines: Cancer; Immunologie; Immunité adaptative; Immunité innée; Immunothérapie

Margaux Vienne, Marion Etiennot, Bertrand Escalière, Justine Galluso, Lionel Spinelli, et al.. Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.768989⟩. ⟨hal-03439141⟩